Mile­stone Phar­ma grabs an $80M round as it steams in­to piv­otal tri­al work, starts out­lin­ing com­mer­cial struc­ture

Eleven years af­ter it got start­ed, Mile­stone Phar­ma­ceu­ti­cals has gained the $80 mil­lion it needs to ex­plore in a piv­otal study whether its new car­dio drug works as ex­pect­ed. And there’s enough mon­ey in the pack­age to start lay­ing the foun­da­tion of a mar­ket­ing ef­fort.

Based in Mon­tre­al, Mile­stone has been pa­tient­ly work­ing on a drug called etri­pamil, a cal­ci­um chan­nel block­er that Mile­stone has for­mu­lat­ed in­to a nasal spray for quick re­lease to halt tachy­car­dias.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER